Browse by category

Genentech announced positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to 24 mg) resulted in significant and clinically meaningful placebo-adjusted weight loss of 22.5% (efficacy estimand) without reaching a weight loss plateau at 48 weeks. CT-388 aims to reduce appetite and

Ring-augmented sleeve gastrectomy (Ra-SG) achieved statistically greater weight-loss durability at 36 months compared with standard sleeve gastrectomy (SG), according to the outcomes from a randomised clinical trial by researchers from Egypt. They also reported that Ra-SG has a lower incidence of clinically significant RWG and smaller gastric pouch volumes at three years. According to the authors, although Ra-SG has the potential to improve SG by placing a non-adjustable ring

The first participants have been dosed in Ascletis Pharma’s US 13-week Phase II study with ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes mellitus. Topline data from the Phase II study are expected in the third quarter of 2026. Ascletis recently completed a 13-week Phase II study evaluating ASC30 for the treatment of obesity in 125 participants with obesity or overweight with at least one weight-related comorbidity at multip

The FDA has cleared Alveus Therapeutics’ Investigational New Drug (IND) application for ALV-100, the company’s lead investigational therapy for chronic weight management, enabling initiation of a Phase 1b clinical study. The first patient was dosed last week. ALV-100 is a bifunctional glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist / glucagon-like peptide-1 receptor (GLP-1R) agonist fusion protein designed to address long-term weight management and tol

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may significantly improve post-surgical outcomes for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and obesity, according to a study led by Cleveland Clinic researchers. At one-year follow-up, patients taking GLP-1RAs showed a 36% reduction in the need for revision sinus surgery. Additionally, at five years post-surgery, patients experienced a 40% reduction in revision surgery rates and a 28% decrease in f

Postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, according to a study led by Mayo Clinic researchers. Concurrent use of hormone therapy and tirzepatide was also associated with improved cardiometabolic outcomes, suggesting that hormone therapy might enhance the therapeutic effects of tirzepatide in this population. "This study provides important insights for developing more effective and personalized strategies for manag

The long-term use of proton pump inhibitors (PPIs), a class of drugs widely used to treat acid reflux and ulcers, may not be linked to any increased risk of developing gastric adenocarcinoma, according to a study of Nordic health data. "The results of this study do not support the hypothesis that long-term proton pump inhibitor use is associated with an increased risk of gastric adenocarcinoma,” the researchers noted. “This finding should offer relief for patients needing lon

Metabolic bariatric surgery (MBS) may improve psoriasis severity, quality of life and treatment requirements - weight loss magnitude, type of MBS and patient characteristics might affect clinical response of psoriasis, however, the current evidence is uncertain, according to researchers from Hull University Teaching Hospitals NHS Trust, in the UK. (Credit: Bobjgalindo) The researchers noted that although MBS has been associated with improved clinical outcomes of psoriasis, ye

The postoperative complications of medical tourism may be costing the NHS up to £20,000 per patient, suggest the findings of a rapid review of the available data performed by UK researchers. However, data on the use, frequency and consequences for the NHS are incomplete and haphazard, making it currently impossible to fully understand the risks of opting for surgery overseas, the researchers warned. "There are areas of the UK, such as Wales and the South West of England, whic

Kailera Therapeutics has announced the randomisation of the first participants in the KaiNETIC global Phase 3 clinical program of ribupatide (also known as KAI-9531), an investigational once-weekly injectable dual GLP-1/GIP receptor agonist peptide, for the treatment of people living with obesity or overweight. The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3